fda stopping tirzepatide The says the Zepbound shortage is over. That's rattling the weight loss industry The legal battle continues –

Here is a new concern about the hidden cost of these miracle shots: slimmer bodies but weaker muscles

Non-Alcoholic Fatty Liver Disease (NAFLD) Semaglutide is currently under investigation as a potential therapy for NAFLD, a prevalent liver condition linked to obesity and metabolic syndrome

The FDA said pharmacies or physicians could face enforcement action if they continued to make or dispense compounded semaglutide products beyond April 22

In cellular and animal models, Cagrilintide exposure has also been associated with measurable changes in metabolic biomarkers, alterations in feeding related signaling circuits, and modulation of pathways connected to gastric motility and energy balance [6]